ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
September 21, 2021 06:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
September 01, 2021 08:00 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
August 16, 2021 16:15 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
August 10, 2021 16:05 ET | ORIC Pharmaceuticals
ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533 IND cleared by FDA; initiation of Phase 1 trial expected in 2H21 IND/CTA filings for ORIC-944 and ORIC-114...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
June 28, 2021 08:00 ET | ORIC Pharmaceuticals
ORIC expects to initiate single agent clinical trial in an undisclosed tumor type in 2H21 ORIC-533 IND filing is the first of three IND/CTA filings expected in 2021 SOUTH SAN FRANCISCO, Calif. and...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
June 02, 2021 16:55 ET | ORIC Pharmaceuticals
Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations ...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 26, 2021 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel
May 25, 2021 08:00 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
May 06, 2021 16:05 ET | ORIC Pharmaceuticals
Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 06,...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting
April 28, 2021 16:05 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...